Dostarlimab: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01539-5
Abstract: Dostarlimab (Jemperli™; GlaxoSmithKline) is a humanized monoclonal antibody programmed death-1 (PD-1) receptor antagonist being developed for the treatment of various cancers. Based on preliminary results from the GARNET trial dostarlimab has recently been approved in… read more here.
Keywords: dostarlimab first; first approval; dostarlimab;
Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
Sign Up to like & getrecommendations! Published in 2021 at "eNeurologicalSci"
DOI: 10.1016/j.ensci.2021.100356
Abstract: Abstract Immune checkpoint inhibitors (ICIs) are being used increasingly in the treatment of several cancers and have been associated with neurological complications including immune checkpoint inhibitor-induced encephalitis (ICI-iE). We present two cases of ICI-iE with… read more here.
Keywords: immune checkpoint; inhibitor induced; dostarlimab; checkpoint ... See more keywords
Dostarlimab for the treatment of advanced endometrial cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2044791
Abstract: ABSTRACT Introduction Between 20% and 30% of the endometrial cancers (EC) are associated with a deficiency of a mismatch repair (MMRd) protein or high microsatellite instability (MSI-H), characteristics that render the tumor more sensitive to… read more here.
Keywords: dostarlimab; platinum containing; treatment advanced; containing regimen ... See more keywords
Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumors: a concentration-QT analysis.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15700
Abstract: AIM Patients with solid tumors were treated with the anti-PD-1 antibody dostarlimab in the Phase I GARNET trial. This study aimed to examine dostarlimab's effect on corrected QT (QTc) interval and the systemic concentration-QTc interval… read more here.
Keywords: patients solid; prolongation; dostarlimab; concentration ... See more keywords